
|Articles|July 1, 2002
Modified steroid has 'potential' for treating subfoveal CNV in AMD
Author(s)Laszlo Dosa
Fort Lauderdale, FL-Anecortave acetate (Alcon), a chemically modified steroid, acts in a unique way to suppress abnormal blood vessel growth in patients with subfoveal choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab
2
New optoretinography technique allows direct measurement of rod function in vivo
3
Long-lived Greenland sharks may point to new approaches for retinal disease
4
FDA grants breakthrough therapy designation to Oculis’ privosegtor for optic neuritis
5












































